Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 14,801–14,900 of 15,747
Can, S. A., Göksever, S., Öz, U. C., Küçüktürkmen, B., Abamor, E. Ş., İnan, M., & Bozkır, A. (2025) · Macromolecular Bioscience · doi:10.1002/mabi.202500397 · Cited by 1
“Despite their proven efficacy, a number of vaccination platforms, such as mRNA, adenovirus-vectored, and inactivated virus vaccines, have significant drawbacks, including adverse effects, stringent storage requirements, and complicated manufacturing procedures [6–8].”
Safety of Pfizer-BioNTech COVID-19 mRNA Vaccine in the ElderlyPreprint
Korzeniowska, K. A., Cieślewicz, A. R., Grabańska-Martyńska, K., & Jabłecka, A. (2021) · Research Square · doi:10.21203/rs.3.rs-1042964/v1
Mutoh, Y., Yamaguchi, T., Sakurai, K., Minato, Y., Izumisawa, T., Kaneko, T., Umemura, T., Mizutani, F., Soejima, K., Hagimoto, S., et al. (2026) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2026.103009
Suzuki, T., Kanemitsu, Y., Sugimoto, N., Masaki, K., Akamatsu, T., Tsurumaki, H., Majima, S., Ito, K., Iwata, T., Shimizu, H., et al. (2026) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2026.18.3.362 · Cited by 1
“3,4 However, many serious adverse events have been reported after COVID-19 mRNA vaccination, including anaphylaxis, myocarditis, and thrombosis.”
Saithong, S., Prompetchara, E., Ketloy, C., Khawsang, C., Tharakhet, K., Kaewpang, P., Yostrerat, N., Wangsoontorn, P., Charsangbong, K., Lam, K., et al. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2686510
“20,21 This led to the fast expansion of mRNA technology to address infectious diseases, cancer, and various other applications, including HPV-related cancers.”
ABDALA, a preventive vaccine against SARS-CoV-2, is safe in Chlorocebus aethiops sabaeus monkeys
Lizet, A., Iliana, S., Carlos, P. J., Mariby, G., Viviana, F., Avelina, L., Rebeca, C., Puente, P., Nancy, E., Valdés, R., et al. (2023) · Advances in Toxicology and Toxic Effects · doi:10.17352/atte.000014
Safe at Last? Late Effects of a Mass Immunization Campaign on Households' Economic Insecurity
Belmonte, A., & Pickard, H. (2022) · Review of Income and Wealth · doi:10.1111/roiw.12643
TÜRKİYE’DE AŞI KARARSIZLIĞI VE BİLİM İLETİŞİMİ: TIBBİ VE SOSYOLOJİK BİR YAKLAŞIM
Övet, C. (2024) · Sosyal ve Beşeri Bilimler Dergisi · doi:10.55978/sobiadsbd.1331672 · Cited by 1
Batchi-Bouyou, A. L., Djontu, J. C., Ingoba, L. L., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3221798/v1
Health Communication on COVID-19 Vaccine Through News Media Text Analysis in China
Liu, Q., Yang, Y., Jia, M., et al. (2024) · Journal of Consumer Health on the Internet · doi:10.1080/15398285.2024.2421675
“COVID-19 has afflicted tens of millions of people in a worldwide pandemic, therefore, many reports have focused on vaccines, because safe and effective vaccines are needed urgently (Polack et al. 2020).”
Underactive and low compliance bladder: A possible Presentation of COVID-19 vaccination
Salehi‐Pourmehr, H., Akbari, N. D., Hajebrahimi, S., & Salehi, S. (2022) · Continence Reports · doi:10.1016/j.contre.2022.100002
Immunization-associated myocarditis post mRNA COVID-19 vaccination: a review article
Núñez, R. D. F. (2022) · Anatomía Digital · doi:10.33262/anatomiadigital.v5i3.1.2259
“Furthermore, clinical trials revealed that the vaccine is safe after a 2month of postvaccination follow-up (31).”
BackgroundCOVID-19 Vaccinations, Infections, and Outcomes Among 784 People Living with HIV
Mahlab‐Guri, K., Komarova, I., Kadar, L., et al. (2024) · Viruses · doi:10.3390/v16121805
Onoja, T., Afere, B. A. E., & Bolaji, B. (2026) · Nonlinear science. · doi:10.1016/j.nls.2026.100212
Modéliser la propagation et le contrôle du SARS-CoV-2 en France
Kiem, C. T. (2022) · theses.fr (ABES) · doi:10.70675/ee2d278bz060dz47c1za2c7zde12caebb50b
Asociación entre la aplicación de la vacuna y la presencia o ausencia de la enfermedad COVID-19
Aguilar, N., & Morales, R. R. (2023) · Revista Medica Sinergia · doi:10.31434/rms.v8i11.1115
Association of Thrombocytopenia in Pregnant Women with COVID-19 Vaccination in the Post-COVID Era
Sultan, K., Khan, S., Tariq, S., Maaz, M., Shahmina, & Akhund, I. I. (2025) · Indus journal of bioscience research. · doi:10.70749/ijbr.v3i6.1659 · Cited by 1
Takeuchi, R., Saito, M., Kurogi, R., Kiyama, N., Yamanishi, Y., Dodo, K., Kamatani, T., Shirasaki, Y., Tsai, C.-H., Yotsumoto, S., et al. (2025) · International Conference on Solid-State Sensors, Actuators and Microsystems · doi:10.1109/transducers61432.2025.11110425
“Thus, the global attention on this technology has surged following the development of mRNA vaccines for COVID-19 that leveraged lipid nanoparticle technology [7, 8, 9].”
Xie, R., He, C., Qiao, S., et al. (2022) · Science and Public Policy · doi:10.1093/scipol/scac021
Singal, M., Kashinath, S. K., Mustafa, S. S., Walsh, E., Vadamalai, K., & Jamshed, S. (2022) · Advances in Clinical Medical Research and Healthcare Delivery · doi:10.53785/2769-2779.1118
Immunization against COVID-19: A Comprehensive Review on the Leading Vaccines
Srinivasan, A., Rajesh, V., Thamilvanan, D., Ganesh, S. K., & Chandrasekaran, S. D. (2023) · Coronaviruses · doi:10.2174/0126667975285709231219080802
Sinovac COVID-19 Side Effects in Hypertensive Patients: An Observational Study From Pakistan
Masood, A., Chohan, H. K., Mubeen, M., Faizan, M., Moin, S., Chohan, M. K., Syed, T., Anwar, A., & Hashmi, A. A. (2023) · Cureus · doi:10.7759/cureus.40444 · Cited by 2
SARS-CoV-2 viral structure and genetics
Pandhi, A., & Vasudev, I. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824409-8.00001-1
Khan, M. I., Sankaran, K. R., & Rahaman, S. O. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.13.705811
(2021) · doi:10.1101/2021.10.11.21264849 · Cited by 45
Kaplanoğlu, V., Kaplanoğlu, H., Turan, A., et al. (2022) · Çukurova medical journal (Online)/Çukurova medical journal · doi:10.17826/cumj.1089995
Innovation Systems Under Crisis: Vaccine Development in Asia and Europe
Storz, C., Lee, K., Kuo, W.-H., & Velte, F. D. (2026) · Springer eBooks · doi:10.1007/978-3-032-24479-6_5 · Cited by 2
Cheng, M. T. K., Keen, J. L., Frost, S., et al. (2026) · medRxiv · doi:10.64898/2026.01.19.26344403
HITE: HIV Inspired Lipid Nanoparticle Platform for CAR T Cell Engineering
Kim, D. K., Moon, S.-J., Han, E. L., Feng, E., Murray, A. M., Wang, J., Liu, W., Kong, G., June, C. H., & Mitchell, M. J. (2026) · Nano Letters · doi:10.1021/acs.nanolett.5c06317
หาญผดุงกิจ, ม., & พุทธเจริญ, โ. (2022) · Chula Digiverse · doi:10.58837/chula.the.2022.1030
Sharma, R., & Anand, A. (2021) · medRxiv · doi:10.1101/2021.06.05.21258394
“The overall efficacy, 76%, is substantially higher than the threshold of 30% often considered as acceptable in Phase 3 trials 16,19 .”
BackgroundChavan, M. N., Gayatri, S., Patil, S. N., Deshpande, J., Yadav, A., Nakate, P., Shelke, Y. P., & Nillawar, A. (2022) · medRxiv · doi:10.1101/2022.01.27.22269902
“SARS-CoV-2 infections in individuals who have already been partially or completely vaccinated with any authorized Covid-19 vaccine.(6) According to the ICMR between 0.”
BackgroundIschemic Colitis in a Middle-Aged Man With COVID-19: Case Report and Review of Literature
Appiah, L., Misra, S., & Jones, S. (2024) · HCA Healthcare Journal of Medicine · doi:10.36518/2689-0216.1362
Shinohara, S., & Hirose, Y. (2023) · Case Reports in Rheumatology · doi:10.1155/2023/4525249
Volkov, O., Borozdenkova, S., & Gray, A. (2022) · medRxiv · doi:10.1101/2022.11.22.22282637
“It reported efficacy estimates for a period between May and November 2020[55], when over 90% of the SARS-CoV-2 infections in the US, and similarly world-wide, were caused by an ancestral strain with the D614G mutation[61].”
BackgroundEl papel de la vacuna SARS-CoV-2 en población con trasplante hepático
Chávez-García, L. C., Juárez-León, Ó. A., Barreda-Mecalco, E., et al. (2021) · Salud Pública de México · doi:10.21149/12666
Parametric Estimation of the Mean Number of Events in the Presence of Competing Risks
Entrop, J. P. P., Jakobsen, L. H., Crowther, M. J., et al. (2025) · Biometrical Journal · doi:10.1002/bimj.70038
“Another example where conducting a recurrent event analysis might provide a more complete picture is in the comparison of (repeated)COVIDinfectionsinclinicaltrialsbydifferentvaccines (Polack et al. 2020).”
Refining the role of behavioural and social sciences in pandemic response post-COVID-19
Graso, M., Aquino, K. F., Baral, S., Berg, N., Clark, C. J., Conway, L. G., Dolan, P. J., Grover, S. L., Fousiani, K., Kitz, C. C., et al. (2026) · Nature Human Behaviour · doi:10.1038/s41562-026-02506-4 · Cited by 1
Özden, Ş., Tepetam, F. M., & Atik, Ö. (2023) · Tuberkuloz ve Toraks · doi:10.5578/tt.20239920 · Cited by 1
Protective characteristics of COVID-19 convalescent and post-vaccination IgG antibodiesPreprint
Klegerman, M. E., Peng, T., Seferovich, I., Rahbar, M. H., Hessabi, M., Tahanan, A., Wanger, A. R., Grimes, C. Z., Ostrosky‐Zeichner, L., Koster, K. J., et al. (2021) · medRxiv · doi:10.1101/2021.11.19.21266547
Agrawal, R. (2021) · Indian Journal of Pathology and Microbiology · doi:10.4103/ijpm.ijpm_177_21
Zero-net mass-flux jet microfluidic delivery platform for multitype cell transfection
Xu, H., Mao, Z., Liu, P., Gao, X., Zhang, M., Ekaterina, V., Hu, G., & Wu, J. (2026) · Physics of Fluids · doi:10.1063/5.0314516
Amani, E., Otroshi, B., Tabatabaie, M., Moslemi, A., & Shabani, S. (2025) · The Clinical Respiratory Journal · doi:10.1111/crj.70127 · Cited by 1
“Currently, results from the clinical evaluations of the various COVID-19 vaccines have provided evidence that they are adequately effective against moderate to severe forms of this infection [24–26].”
Safety of Heterologous mRNA Vaccine Booster in Healthy Adults
Yu, Q. (2023) · Epidemiology International Journal · doi:10.23880/eij-16000257
Hamaya, T., Hatakeyama, S., Yoneyama, T., Tobisawa, Y., Kodama, H., Fujita, T., Murakami, R., Fujita, N., Okamoto, T., Yamamoto, H., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-1120488/v1
The MYB-related transcription factor MYPOP acts as a selective regulator of cancer cell growth
Strunk, J., Hüppner, A., Sial, M., Plath, M., Sheriff, M. B., Wagner, S., Freitag, K., Mikuličić, S., Döring, T., Bopp, T., et al. (2026) · Communications Biology · doi:10.1038/s42003-026-10272-2 · Cited by 1
Wu, X., Yao, J., Qian, J., Huang, Q.-F., Deng, T., Xu, S.-Q., Wang, H.-F., Li, Q., Peng, J., Yang, Y., et al. (2022) · Journal of Acute Disease · doi:10.4103/2221-6189.336575
Manifestaciones neurológicas en pacientes con diagnóstico de COVID-19
Cabrera, B. R. M., Benavides, A. L. O., & Nivelo, I. I. O. (2023) · Revista Virtual de la Sociedad Paraguaya de Medicina Interna · doi:10.18004/rvspmi/2312-3893/2023.10.01.74 · Cited by 3
Autolysosomal degradation-inhibitory nanoparticles for enhanced mRNA escape and cytokine therapy
Zhou, T.-Q., Sun, W., Yang, H., Zhang, G., Naeem, A., Weng, Y., Zhu, M., Wei, Z.-Z., Huang, Y., & Liang, X. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2026.100593
(2021) · Zeitschrift für Allgemeinmedizin · doi:10.1007/bf03652873
Qasim, G. A., Arulselvam, V., Amer, S. R. A., Alghanem, S., & Kalis, N. N. (2021) · Journal of the Bahrain Medical Society · doi:10.26715/jbms.33_2021_4_7
Shoukat, A., Galvani, A. P., & Fitzpatrick, M. C. (2021) · medRxiv · doi:10.1101/2021.03.31.21254646
COVID-19’s Natural Course Among Ambulatory Monitored OutpatientsPreprint
Weinbergerová, B., Mayer, J., Hrabovský, Š., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-148835/v1
Wangteeraprasert, A., Pongcharoen, S., Ngoenkam, J., & Makanut, S. (2025) · mSphere · doi:10.1128/msphere.00722-25
“This vaccine had an efficacy of 95% in preventing COVID-19 at 7 days after the second dose (13).”
Kim, J., Sim, J., Park, S., Ma, J., Kim, J., Kum, Y., Lee, H., Huh, I., Lee, J., Kim, Y.-J., et al. (2026) · Pharmaceutical Research · doi:10.1007/s11095-026-04175-4
“The advantages of mRNA vaccines over traditional vaccines (e.g., inactivated, attenuated, and protein subunit vaccines) include rapid production, adaptability to variants, and strong immunogenicity [3].”
Sarhan, I. I., Abdelgawad, M. A., Emara, A. A., Elkader, M. A. A., & Mohamed, A. F. (2024) · Journal of The Egyptian Society of Nephrology and Transplantation · doi:10.4103/esnt.esnt_12_24
Sriram, V., Conard, A. M., Rosenberg, I., Kim, D., & Hall, A. K. (2024) · medRxiv · doi:10.1101/2024.03.15.24304358 · Cited by 2
Garcia, M. T. P., Valim, V., & Lopes‐Júnior, L. C. (2026) · Health Science Reports · doi:10.1002/hsr2.72824
5‐Ethynyluridine: A Bio‐orthogonal Uridine Variant for mRNA‐Based Therapies and Vaccines
Maassen, S., Coenen, B. A., Dülk, S.-L., van der Werff, M., Warner, H. M., Spada, F., Frischmuth, T., Incarnato, D., & van den Bogaart, G. (2023) · ChemBioChem · doi:10.1002/cbic.202200658
Yildiz, M., Genç, A. C., Genç, A. B., Çekiç, D., & Yaylacı, S. (2026) · Cerasus journal of medicine. · doi:10.70058/cjm.1928830 · Cited by 1
COVID-19 Vaccine Comparison: How to Choose the Best Suiting Vaccine for Different Needs
Liu, C., Lu, A., & Wu, X. O. (2021) · E3S Web of Conferences · doi:10.1051/e3sconf/202129203080
Applications of nanoengineered therapeutics and vaccines: special emphasis on COVID-19
Mohamed, N. K., Hamad, M. A., Ghaleb, A. H., Esmat, G., & Elsabahy, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90604-3.00003-6
Public investment on health and voter responses: Evidence from the mass vaccination during COVID-19
Takahashi, M., Takaku, R., Ashida, T., & Ibuka, Y. (2025) · European Journal of Political Economy · doi:10.1016/j.ejpoleco.2025.102718 · Cited by 3
USING MRNA VACCINES TO ENDANGER POPULATION IS A RECURRENT HUMANITY DISASTER
Wu, J., & D., J. J. S. P. (2022) · International Journal of Education Humanities and Social Science · doi:10.54922/ijehss.2022.0373
Why it matters that the coronavirus is changing – and what this means for vaccine effectiveness
Kennedy, D. A. (2020) · The Conversation · doi:10.64628/aai.ejnxnv3m9
mRNA Vaccination for Breast Cancer
Schmidt, M., & Sahin, U. (2024) · Cancer immunotherapy · doi:10.1007/13905_2024_46
Fuller, J. (2025) · Oxford University Press eBooks · doi:10.1093/9780190066178.003.0002
Regulatory considerations for the use of biomaterials in medical applications
Jasim, A. A., Esther, A., & Greish, K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-26657-7.00023-4
Begum, R. F., Mathew, M., Doshi, P. P., & Suresh, S. (2026) · Immunologic Research · doi:10.1007/s12026-026-09757-3
Moszczynski, A. J., & Hintermayer, M. A. (2021) · McGill Journal of Medicine · doi:10.26443/mjm.v19i1.834
Silva, A. L. M. D. M., Araújo, A. P. S. D., Lima, V. H. A., & de Oliveira, C. M. (2023) · Brazilian Journal of Health Review · doi:10.34119/bjhrv6n3-318
Interactions hôtes/lentivirus et contrôle de l'infection avec des vaccins LentiDNA innovants
Chergui, H. E. (2024) · theses.fr (ABES) · doi:10.70675/53cd7138z7fedz42f7zb5c3zb18ef5a33362
Calderón, O. M. (2020) · Arquivos de Asmas Alergia e Imunologia · doi:10.5935/2526-5393.20200055
Lin, C. (2022) · Research Square · doi:10.21203/rs.3.rs-1850180/v1
“In reality, the Pfizer vaccine requires two separate shots, with the first dose only providing 52% efficacy [47].”
BackgroundEnough with the madness: a systematic review and meta-analysis of hydroxychloroquine for COVID-19
Santos, A., Gonçalves, É. S. D., Oliveira, A., Lima, D., Noronha, K., & Andrade, M. (2021) · Jornal Brasileiro de Economia da Saúde · doi:10.21115/jbes.v13.n2.p186-220
Medical Ethics and Informed Consent to Treatment: Past, Present and Future
Mordue, A., A, E. E., Royle, J., & Craig, C. E. H. (2024) · Cureus · doi:10.7759/cureus.75377 · Cited by 2
Young, A. M. H., Neumann, B., Stoll, G. A., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4124048
Ferrazza, G., Nucera, A., Longo, S., Ferrari, C., Mazza, A., Magrini, A., Coppeta, L., & Rizza, S. (2023) · The Open Public Health Journal · doi:10.2174/0118749445268028230921100630
Dabilgou, A. A., Ouédraogo, É., Kyelem, J. M. A., Dravé, A., Wanré, O., Napon, C., & Millogo, A. (2025) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-025-10249-8
“The side effects of the COVID-19 vaccine were reported by 30% to 90% of participants in ran - domised clinical trials of the COVID-19 vaccines (Baden et al. 2021 ; Polack et al. 2020).”
Zhou, M., Liu, J., Zhang, X., Yan, F., Wu, Y., Huang, C., Xie, D., & Liu, B. (2026) · Vaccines · doi:10.3390/vaccines14050389
“Continuous viral evolution and the emergence of immune-evasive variants have increased the demand for vaccines capable of inducing broader and more durable protection [17,18].”
Sukik, L., Paul, P., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., et al. (2026) · International Journal of Epidemiology · doi:10.1093/ije/dyag210
Multifunctional nanocomposites for precise control over drug delivery
Andretto, V. (2022) · theses.fr (ABES) · doi:10.70675/7a7f57fez25f2z41a0z9072z3f3cc2aef2d6
Gong, D., Xie, X., Tang, J., Li, S., & Li, H. (2026) · Briefings in Bioinformatics · doi:10.1093/bib/bbag092 · Cited by 1
“The recent successful deployment of LNPs as delivery vehicles for COVID-19 mRNA vaccines (mRNA-1273 and BNT162b2) in the immunoprophylaxis of SARS-CoV-2 infection has generated substantial interest in R NA-LNPs delivery systems [9, 10].”
Dong, Z., Li, S., Guo, J., et al. (2026) · Research in Veterinary Science · doi:10.1016/j.rvsc.2026.106359
Koller, Á., Pelle, J., Béres, B., & Takács, J. (2024) · Sprint, sports research international · doi:10.1556/1020.2023.10001
COVID-19 Incidence and Disease Course Among Patients at an Allergy Department
van der Aa, L. E., van Egmond, I. S., van der Sluijs, M., et al. (2023) · Therapeutic Advances in Allergy and Rhinology · doi:10.1177/27534030231172391
Minimizing the Epidemic Final Size while Containing the Infected Peak Prevalence in SIR SystemsPreprint
Sereno, J. E., Anderson, A., Ferramosca, A., et al. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2111.05652
REACTIVE NON-REGIONAL LYMPHADENOPATHY FROM THE COVID-19 mRNA VACCINE: A NOVEL SIDE-EFFECT.
Gidwani, R., Siddiqui, S. A., & Prabhavalkar, S. M. (2022) · PubMed
Kemnitz, M. P. (2021) · Evidencia actualizacion en la práctica ambulatoria · doi:10.51987/evidencia.v24i4.6958
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.